Edgewise Therapeutics, Inc.
EWTX
주식 순위
#3882
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
주가
$39.70
시가총액
$4.27B
변동 (1일)
-0.12%
변동 (1년)
155.98%
국가
US
거래 Edgewise Therapeutics, Inc. (EWTX)
카테고리
Healthcare
Edgewise Therapeutics, Inc. (EWTX)의 주가 이력
최고 종가: $38.97 (2026-10-01 기준)
최저 종가: $32.43 (2021-03-01 기준)
최저 종가: $32.43 (2021-03-01 기준)
Edgewise Therapeutics, Inc.의 주가 이력 (2021 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 37.71% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
